Harini de Silva’s background is in immunology and infectious disease. She has broad experience in the areas of autoimmunity, allergy, malaria vaccines and infections in the immunocompromised host. In 2002, Harini joined a multidisciplinary team at Monash Microbiology to work on a malaria vaccine development project funded by the Gates Foundation. In 2009 Harini moved to the Burnet Immunomonitoring Facility and managed the quality accreditation project that enabled this facility to become the first NATA accredited R&D laboratory in Victoria. Harini’s current research focuses on diagnostic and biomarker assays for opportunistic infections in immunocompromised patients such as those undergoing stem cell transplantation.
Harini has a wide range of skills including cellular and molecular immunology, development and validation of immunoassays, project management, quality management, clinical trial and clinical registry co-ordination and immunology teaching.
- Member of Australian Society of Immunology (ASI)
- Member of International Society for Human and Animal Mycology (ISHAM)
- Member of the Victorian Infection and Immunity Network (VIIN)
- 2011-Current: Senior Research Officer, Burnet Institute
- 2014-2015: Research Fellow, Department of Epidemiology, Monash University
- 2009-2011: Project Manager, Burnet ImmunoMonitoring Facility
- 2002-2009: Research Fellow, Malaria Vaccine Initiative, Monash University Adjunct Lecturer, Department of Microbiology, Monash University
- 1998-2002: Research Fellow, Department of Immunology, Monash University
- 1998: PhD, Monash University, Australia
- 1992: BSc (Hons), Monash University, Australia
- Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies.
Heng SC, Chen SC, Morrissey CO, Thursky K, Manser RL, De Silva HD, Halliday CL, Seymour JF, Nation RL, Kong DC, Slavin MA
Diagn Microbiol Infect Dis. 2014 Mar; 79(3):322-327
- The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
de Silva HD, Saleh S, Kovacevic S, Wang L, Black CG, Plebanski M, Coppel RL
Malar J. 2011 Sep; 10:266
- Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria.
Salwati E, Minigo G, Woodberry T, Piera KA, de Silva HD, Kenangalem E, Tjitra E, Coppel RL, Price RN, Anstey NM, Plebanski M
J Infect Dis. 2011 Apr; 203(8):1192-1199
- Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses.
Tonia Woodberry, Gabriela Minigo, Kim A Piera, Jennifer C Hanley, Harini D de Silva, Ervi Salwati, Enny Kenangalem, Emiliana Tjitra, Ross L Coppel, Ric N Price, Nicholas M Anstey, Magdalena Plebanski
J Infect Dis. 2008 Jul; 198(1):134-142
- Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity.
Alexander C Drew, Nirupama P Eusebius, Linda Kenins, Harini D de Silva, Cenk Suphioglu, Jennifer M Rolland, Robyn E O'hehir
J Immunol. 2004 Nov; 173(9):5872-5879
- The hevein domain of the major latex-glove allergen Hev b 6.01 contains dominant T cell reactive sites.
H D de Silva, L M Gardner, A C Drew, D H Beezhold, J M Rolland, R E O'Hehir
Clin Exp Allergy. 2004 Apr; 34(4):611-618